Current issues in assuring virological safety of biopharmaceuticals

BioProcess International

Volumn 10, Issue 3, 2012, Pages 12-17

  Aranha, Hazel ^a  

^a CATALENT PHARMA SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LIVE VACCINE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; VIRUS VACCINE;

AEDES ALBOPICTUS; ARBOVIRUS; CHIKUNGUNYA ALPHAVIRUS; CIRCOVIRUS; DISEASE CARRIER; DRUG CONTAMINATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; HUMAN; MICROARRAY ANALYSIS; MURINE LEUKEMIA VIRUS; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS STRAIN;

EID: 84858956950     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (31)

1. PhRMA. Biotechnology Medicines in Development. Pharmaceutical Research and Manufacturers of America: Washingtion, DC, 2011.
2. DiMasi JA, Feldman L, Seckler A, Trends in Risks Associated with New Drug Development: Success Rates for Investigational drugs. Clin. Pharmacol. Ther. 87, 2010: 272-277.
3. Ludwig B. High-Development Costs, Complex Manufacturing, and Legal Hurdles Are Holding Back Generic Drugmakers Seeking to Copy Pricey Biotech Medications Nearing the End of Their Patents. Reuters 2 July 2010. accessed 21 December 2011 at: http://uk.reuters.com/article/2010/07/02/biosimilar-drugs- idUKLNE66102R20100702?rpc=401&feedType=RSS&feedName=stocksNews&rpc= 401. 2010.
4. Wiebe ME. Conventional Virus Assays and the Need for New Technologies. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, 2-4 Nov 2011, Rockville, MD.
5. ICH Q5A (R1): Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin. US Fed. Reg. 23 Sept 1999: 9-10.
6. Bethencourt V. Virus Stalls Genzyme Plant. Nat. Biotech. 27(8) 2009: 681.
7. Kerr A, Nims R. Adventitious Viruses Detected in Biopharmaceutical Bulk Harvest Samples Over a 10-Year Period. PDA J. Pharm. Sci. Technol. 64(5) 2010: 481-485.
8. Moody M. MMV Contamination, a Case Study: Detection, Root Cause Determination and Corrective Actions. PDA/FDA Adventitious Viruses in Biologics Detection and Mitigation Strategies Workshop, 1-3 December 2010, Rockville, MD.
9. Skrine J. A Biotech Production Facility Contamination Case Study - Mouse Minute Virus. PDA/FDA Adventitious Viruses in Biologics Detection and Mitigation Strategies Workshop, 1-3 December 2010, Rockville, MD.
10. Pastoret PP. Human and Animal Vaccine Contaminations. Biologicals 38(3) 2010: 332-334.
11. Woolhouse ME, et al. Temporal Trends in the Discovery of Human Viruses. Proc. Biol. Sci. 275(1647) 2008: 2111-2115.
12. Meehan BM, et al. Sequence of Porcine Circovirus DNA: Affinities with Plant Circoviruses. J. Gen. Virol. 78 (Pt 1) 1997: 221-227. (Pubitemid 27067534)
13. Cool M, et al. No Detectable XMRV in Subjects with Chronic Fatigue Syndrome from Quebec. Virology 420(1) 2011: 66-72.
14. Simon F, Savini H, and Parola P. Chikungunya: A Paradigm of Emergence and Globalization of Vector-Borne Diseases. Med. Clin. North Am. 92(6) 2008: 1323-1343.
15. Boneva RS, Folks TM. Xenotransplantation and Risks of Zoonotic Infections. Ann. Med. 36(7) 2004: 504-517. (Pubitemid 39490960)
16. Yamanouchi K. Potential Risk of Xenotransplant-Associated Infections. Transplant Proc. 32(5) 2000: 1155-1156. (Pubitemid 30601927)
17. Aranha H. Virological Safety of Biopharmaceuticals. A Risk-Based Approach. Bioprocess Int. 4(10) 2005: S17-S20.
18. Lower J. Risks Associated with Cell Substrates and Other Biological Materials and Product Safety. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, 2-4 Nov 2011, Rockville, MD, 2011.
19. Tagmyer T. Evaluating Safety of Vendor Sourced Raw Materials Used in Vaccine Manufacturing. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, 2-4 Nov 2011, Rockville, MD, 2011.
20. Mackay D, Kriz N. Current Challenges in Viral Safety and Extraneous Agent Testing. Biologicals 38(3) 2010: 335-337.
21. Potts BJ. TSE Case Studies Associated with Japanese and Other Regulatory Authoritie: Talk Transcript. PDA J. Pharm. Sci. Technol. 64(5) 2010: 442-444.
22. Rubino MJ. Raw Materials Case Histories. PDA J. Pharm. Sci. Technol. 64(5) 2010: 440-441.
23. Dehghani H. State of the Art for Monitoring and Ensuring Biosafety in Manufacturing. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, 2-4 Nov 2011, Rockville, MD.
24. Gauvin G, Nims R, Gamma-Irradiation of Serum for the Inactivation of Adventitious Contaminants. PDA J. Pharm. Sci. Technol. 64(5) 2010: 432-435.
25. Weaver B, Rosenthal S. Viral Risk Mitigation for Mammalian Cell Culture Media. PDA J. Pharm. Sci. Technol. 64(5) 2010: 436-439.
26. Motitschke A, Ottiger HP, Jungback C. Evaluation of the Sensitivity of PCR Methods for the Detection of Extraneous Agents and Comparison with In Vivo Testing. Biologicals 38(3) 2010: 389-392.
27. Lubiniecki AS. Closing Remarks. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, 2-4 Nov 2011, Rockville, MD.
28. Khan AS. Investigations of New Technologies for Latent Virus Detection. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, 2-4 Nov 2011, Rockville, MD.
29. Hammond R. Risks Associated with Plant Viruses and Viroids. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, 2-4 Nov 2011, Rockville, MD.
30. Stacey G. New WHO Guidance on Evaluation of Cell Substrates and Considerations for Insect Cell Substrates. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, 2-4 Nov 2011, Rockville, MD.
31. Marcus-Sekura C, et al. Evaluation of the Human Host Range of Bovine and Porcine Viruses that May Contaminate Bovine Serum and Porcine Trypsin Used in the Manufacture of Biological Products. Biologicals 39(6) 2011: 359-369.